Florida Physician and Staff Charged in Alleged Clinical Trial Data Falsification Scheme
核心洞察
Federal prosecutors have charged Dr. Jaynier Moya (搜索) and three clinical research coordinators with conspiring to falsify data in industry-sponsored drug trials at Pines Care Research Center (搜索) in Florida.
The alleged scheme, dating back to at least 2019, involved fabricating records to show participants took investigational drugs and underwent protocol-required testing when they had not.
Prosecutors allege falsified test data was submitted into clinical trial database systems used to evaluate prospective new drugs for FDA approval.
Federal prosecutors have charged a Florida physician and three clinical research coordinators in connection with an alleged scheme to falsify data in industry-sponsored clinical drug trials, the U.S. Department of Justice announced. The case raises significant concerns about data integrity in the pharmaceutical development pipeline, as prosecutors allege the fabricated information was not confined to site-level records but entered clinical trial database systems used to evaluate prospective new drugs.
Dr. Jaynier Moya (搜索), 49, of Southwest Ranches, Florida, co-owner and principal investigator at Pines Care Research Center (搜索) LLC in Pembroke Pines, Florida, was charged alongside clinical research coordinators Luis Montano, 55, of Hialeah, Florida; Yuniarka Garcia, 41, of Plantation, Florida; and Alexandra Olivera, 38, of Hialeah, Florida. The charges were brought by a federal grand jury in the Southern District of Florida, with Olivera charged separately in a criminal information.
Alleged Misconduct
According to the charging documents, the alleged misconduct began no later than 2019. The defendants are accused of fabricating testing data and falsifying records while conducting clinical trials sponsored by a pharmaceutical development company. Prosecutors allege the defendants created records suggesting that study participants had taken investigational medications and undergone protocol-required testing to evaluate the study medications' effects when, in fact, they had not.
The indictment further alleges that identification documents from individuals who did not actually participate in the trials were used to create false participant records and generate test results. "The trials were designed to test prospective new drugs to evaluate their safety and efficacy for potential approval by the FDA," according to the Department of Justice.
Impact on Drug Development Pipeline
The significance of the case extends beyond site-level misconduct. According to the Justice Department, the alleged scheme caused falsified test data to be submitted into the clinical trial database systems used for evaluating prospective new drugs. This means that downstream analyses and regulatory evaluation — processes that depend on the accuracy of information generated during trial conduct — may have been compromised.
The case underscores why data integrity at research sites is central to confidence in clinical development. Regulatory evaluation by the FDA and other agencies relies fundamentally on the accuracy and reliability of data submitted from trial sites.
Charges and Potential Penalties
Each defendant is charged with conspiracy to commit wire fraud. Moya, Montano, and Garcia are each also charged with three counts of substantive wire fraud. If convicted, each defendant faces a statutory maximum penalty of 20 years in prison for conspiracy to commit wire fraud. Moya, Montano, and Garcia also face a statutory maximum penalty of 20 years in prison per count upon conviction of substantive wire fraud.
The case is being investigated by the FDA's Office of Criminal Investigations Miami Field Office and prosecuted by Trial Attorneys Andrew Crawford and Brianna Gardner of the Criminal Division's Health and Safety Unit. Assistant Attorney General A. Tysen Duva of the Justice Department's Criminal Division and Acting Special Agent in Charge Juan Berrios of the FDA's Office of Criminal Investigations Miami Field Office made the announcement.
The Health and Safety Unit within the Department's Criminal Division works with law enforcement partners to investigate and prosecute violations of federal laws designed to protect public health and safety, focusing on corporations and individuals who make and sell dangerous drugs, food, and other consumer products that could cause significant harm to Americans.
The indictment and criminal information are allegations, and all defendants are presumed innocent unless proven guilty beyond a reasonable doubt in a court of law.